September 2016
As Metformin Combinations Proliferate, Questions Arise About Value
September 21st 2016For some patients newly diagnosed with type 2 diabetes, skipping metformin monotherapy and going straight to fixed-dose combinations with a DPP-4 inhibitor or an SGLT2 inhibitor makes sense, evidence shows.
Representativeness of Dipeptidyl-Peptidase-4 Inhibitor Cardiovascular Outcomes Trials
Given the growing prevalence of type 2 diabetes (T2D) and its contribution to cardiovascular disease, cardiovascular outcomes trials should aim to be more representative of the average patient with T2D.
Intarcia Poised to Seek FDA Approval for ITCA 650 After Positive A1C, CV Results
September 19th 2016Officials say the company will file with FDA some time in the third quarter of 2016 to begin the approval process for the novel delivery system that brings a continuous, microscopic dose of exenatide to patients with type 2 diabetes.
Discussions of High Costs for New Therapies Raise Questions About an Old One: Insulin
September 19th 2016Robert A. Gabbay, MD, PhD, FACP, editor-in-chief of Evidence-Based Diabetes Management, discusses the complexities of the current debate over the cost of insulin.
Patients Report Barriers to Getting Afrezza, but A1C Results Are Worth It
September 16th 2016Gaining access to Afrezza can mean battling with an insurer to cover it. Sometimes the first hurdle is getting a doctor to write a prescription, according to those who've been through the process.
Afrezza: Treating Diabetes in a Physiologic Manner
September 16th 2016Professor R. Keith Campbell, MBA, BPharm, CDE, now retired from Washington State University College of Pharmacy, highlights the clinical advantages of Afrezza based on the evidence as well as his personal perspective.
